Interpace Biosciences Inc
OTC:IDXG
Interpace Biosciences Inc
Accrued Liabilities
Interpace Biosciences Inc
Accrued Liabilities Peer Comparison
Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Interpace Biosciences Inc
OTC:IDXG
|
Accrued Liabilities
$8.9m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-7%
|
|
DaVita Inc
NYSE:DVA
|
Accrued Liabilities
$1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Accrued Liabilities
$153m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
CVS Health Corp
NYSE:CVS
|
Accrued Liabilities
$24.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
17%
|
|
Cigna Corp
NYSE:CI
|
Accrued Liabilities
$8.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Accrued Liabilities
$820.6m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
9%
|
See Also
What is Interpace Biosciences Inc's Accrued Liabilities?
Accrued Liabilities
8.9m
USD
Based on the financial report for Mar 31, 2024, Interpace Biosciences Inc's Accrued Liabilities amounts to 8.9m USD.
What is Interpace Biosciences Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
-7%
Over the last year, the Accrued Liabilities growth was 13%. The average annual Accrued Liabilities growth rates for Interpace Biosciences Inc have been -4% over the past three years , 7% over the past five years , and -7% over the past ten years .